Trademarkia Logo

Canada

C$
ENBREVIS
REGISTERED

on 22 Nov 2019

Last Applicant/ Owned by

Merz Pharmaceuticals, LLC

6601 Six Forks Road, 4th FlrRaleigh, NC 27615

US

Serial Number

1866198 filed on 3rd Nov 2017

Registration Number

TMA1064013 registered on 22nd Nov 2019

Registration expiry Date

22nd Nov 2029

Correspondent Address

PIASETZKI NENNIGER KVAS LLP

SUITE 2308120 ADELAIDE STREET WESTTORONTO

ONTARIO

CA

M5H1T1

ENBREVIS

Trademark usage description

pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous sys Read More

Classification Information


Class [005]
Pharmaceutical products, namely, pharmaceutical and biological preparations for the treatment of diseases, disorders and conditions of the nervous system namely brain, movement, ocular motility, autoimmune and spinal cord diseases, disorders and conditions; pharmaceutical and biological preparations for the treatment of Parkinson's Disease, multiple sclerosis, Alzheimer's Disease and epilepsy.


Classification kind code

11

Class [010]
Medical devices, namely inhaler and nebulizer delivery devices that facilitate delivery of pharmaceutical and biological preparations used in the treatment of diseases, disorders and conditions of the nervous system.


Classification kind code

11

Mark Details


Serial Number

1866198

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 13th Nov 2019
Registration Pending
Submitted for opposition 42
on 21st Aug 2019
Advertised
Submitted for opposition 26
on 31st Jul 2019
Approved
Submitted for opposition 27
on 31st Jul 2019
Approval Notice Sent
Submitted for opposition 15
on 29th Jan 2019
Correspondence Created
Submitted for opposition 22
on 12th Dec 2018
Search Recorded
Submitted for opposition 20
on 12th Dec 2018
Examiner's First Report
Submitted for opposition 1
on 6th Nov 2017
Created
Submitted for opposition 31
on 6th Nov 2017
Formalized
Submitted for opposition 30
on 3rd Nov 2017
Filed